ProCE Banner Activity

CE

Stroke Prevention With Evidence-Based DOAC Therapy

Multimedia

In this microlearning module, an expert faculty provides evidence-based recommendations on the use of DOAC therapy in NVAF for stroke prevention.

Pharmacists : 0.50 contact {hour} ({0.05} CEUs)

Released: April 13, 2022

Expiration: April 12, 2023

No longer available for credit.

Share

Faculty

Stephanie Dwyer Kaluzna

Stephanie Dwyer Kaluzna, PharmD, BCCP

Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago College of Pharmacy
Cardiovascular Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Chicago, Illinois

Kathleen A. Lusk

Kathleen A. Lusk, PharmD, BCPS, BCCP

Associate Professor
Vice Chair
Department of Pharmacy Practice
University of the incarnate Word Feik School of Pharmacy
San Antonio, Texas

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb and Pfizer Alliance.

Bristol Myers Squibb

Pfizer Alliance

Target Audience

The target audience is pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with or at risk for NVAF. In addition, the target audience includes pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guideline recommendations, clinical trial evidence, and patient-specific factors to select DOACs for appropriate patients diagnosed with NVAF

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Kathleen A. Lusk, PharmD, BCPS, BCCP, has no relevant conflicts of interest to report.

Staff Disclosure

Kimberly Nealy, PharmD, BCPS, CDCES, CPP, has no relevant conflicts of interest to report.

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Susan Daniels, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-032-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 0.5 contact hours (0.05 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 100% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure of Unlabeled Use

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 13, 2022, through April 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 13, 2022, through April 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve the knowledge, competence, and performance of pharmacists regarding the implications of undiagnosed NVAF, types of detection for NVAF, the need to counsel and follow up with individuals who are at risk for or detected/diagnosed with NVAF, and the need to enhance collaboration with other HCPs to improve patient care.